JP2004520282A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004520282A5 JP2004520282A5 JP2002544401A JP2002544401A JP2004520282A5 JP 2004520282 A5 JP2004520282 A5 JP 2004520282A5 JP 2002544401 A JP2002544401 A JP 2002544401A JP 2002544401 A JP2002544401 A JP 2002544401A JP 2004520282 A5 JP2004520282 A5 JP 2004520282A5
- Authority
- JP
- Japan
- Prior art keywords
- cyano
- ethoxy
- guanidino
- chlorophenoxy
- hexyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- -1 nitro, amino Chemical group 0.000 claims 55
- 150000001875 compounds Chemical class 0.000 claims 36
- 229910052739 hydrogen Inorganic materials 0.000 claims 14
- 239000001257 hydrogen Substances 0.000 claims 14
- 229910052736 halogen Inorganic materials 0.000 claims 11
- 150000002367 halogens Chemical class 0.000 claims 11
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 125000000217 alkyl group Chemical group 0.000 claims 10
- 230000000118 anti-eoplastic Effects 0.000 claims 9
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 9
- 201000011510 cancer Diseases 0.000 claims 8
- 125000004093 cyano group Chemical group *C#N 0.000 claims 7
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 7
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims 6
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims 6
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 claims 6
- 201000010099 disease Diseases 0.000 claims 6
- 239000000203 mixture Substances 0.000 claims 6
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 5
- 125000000753 cycloalkyl group Chemical group 0.000 claims 5
- 125000001072 heteroaryl group Chemical group 0.000 claims 5
- 150000002431 hydrogen Chemical group 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 239000004215 Carbon black (E152) Substances 0.000 claims 4
- 125000003118 aryl group Chemical group 0.000 claims 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 4
- 229910052760 oxygen Inorganic materials 0.000 claims 4
- 230000002062 proliferating Effects 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- JIHQDMXYYFUGFV-UHFFFAOYSA-N 1,3,5-Triazine Chemical class C1=NC=NC=N1 JIHQDMXYYFUGFV-UHFFFAOYSA-N 0.000 claims 3
- GHASVSINZRGABV-UHFFFAOYSA-N 5-flurouricil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 3
- AOJJSUZBOXZQNB-TZSSRYMLSA-N ADRIAMYCIN Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims 3
- 229940100198 ALKYLATING AGENTS Drugs 0.000 claims 3
- 229940100197 ANTIMETABOLITES Drugs 0.000 claims 3
- 229940064005 Antibiotic throat preparations Drugs 0.000 claims 3
- 229940083879 Antibiotics FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 claims 3
- 229940042052 Antibiotics for systemic use Drugs 0.000 claims 3
- 229940042786 Antitubercular Antibiotics Drugs 0.000 claims 3
- 229960004562 Carboplatin Drugs 0.000 claims 3
- OLESAACUTLOWQZ-UHFFFAOYSA-L Carboplatin Chemical compound O=C1O[Pt]([N]([H])([H])[H])([N]([H])([H])[H])OC(=O)C11CCC1 OLESAACUTLOWQZ-UHFFFAOYSA-L 0.000 claims 3
- JCKYGMPEJWAADB-UHFFFAOYSA-N Chlorambucil Chemical compound OC(=O)CCCC1=CC=C(N(CCCl)CCCl)C=C1 JCKYGMPEJWAADB-UHFFFAOYSA-N 0.000 claims 3
- 229960004630 Chlorambucil Drugs 0.000 claims 3
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims 3
- 229960004397 Cyclophosphamide Drugs 0.000 claims 3
- 229960004679 Doxorubicin Drugs 0.000 claims 3
- 229960005420 Etoposide Drugs 0.000 claims 3
- VJJPUSNTGOMMGY-MRVIYFEKSA-N Etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 3
- 229960002949 Fluorouracil Drugs 0.000 claims 3
- SDUQYLNIPVEERB-QPPQHZFASA-N Gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 3
- 229940093922 Gynecological Antibiotics Drugs 0.000 claims 3
- 229940088597 Hormone Drugs 0.000 claims 3
- RCINICONZNJXQF-MZXODVADSA-N Intaxel Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 3
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N Melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims 3
- 229960001592 Paclitaxel Drugs 0.000 claims 3
- 229940024982 Topical Antifungal Antibiotics Drugs 0.000 claims 3
- 229960004528 Vincristine Drugs 0.000 claims 3
- 239000002168 alkylating agent Substances 0.000 claims 3
- 239000004037 angiogenesis inhibitor Substances 0.000 claims 3
- 229940121369 angiogenesis inhibitors Drugs 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 230000000340 anti-metabolite Effects 0.000 claims 3
- 239000002256 antimetabolite Substances 0.000 claims 3
- 125000002029 aromatic hydrocarbon group Chemical group 0.000 claims 3
- 230000003115 biocidal Effects 0.000 claims 3
- 230000032823 cell division Effects 0.000 claims 3
- 239000003795 chemical substances by application Substances 0.000 claims 3
- 229960004316 cisplatin Drugs 0.000 claims 3
- 229960005277 gemcitabine Drugs 0.000 claims 3
- 239000005556 hormone Substances 0.000 claims 3
- 125000001183 hydrocarbyl group Chemical group 0.000 claims 3
- 239000000367 immunologic factor Substances 0.000 claims 3
- 239000003112 inhibitor Substances 0.000 claims 3
- 230000002401 inhibitory effect Effects 0.000 claims 3
- 229940079866 intestinal antibiotics Drugs 0.000 claims 3
- 229960001924 melphalan Drugs 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229940005935 ophthalmologic Antibiotics Drugs 0.000 claims 3
- 238000007911 parenteral administration Methods 0.000 claims 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 229930003347 taxol Natural products 0.000 claims 3
- LXZZYRPGZAFOLE-UHFFFAOYSA-L transplatin Chemical compound [H][N]([H])([H])[Pt](Cl)(Cl)[N]([H])([H])[H] LXZZYRPGZAFOLE-UHFFFAOYSA-L 0.000 claims 3
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 3
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 claims 3
- 229960002066 vinorelbine Drugs 0.000 claims 3
- ASQUQUOEFDHYGP-UHFFFAOYSA-N 2-methoxyethanolate Chemical group COCC[O-] ASQUQUOEFDHYGP-UHFFFAOYSA-N 0.000 claims 2
- 206010000880 Acute myeloid leukaemia Diseases 0.000 claims 2
- 206010005003 Bladder cancer Diseases 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 2
- 206010008342 Cervix carcinoma Diseases 0.000 claims 2
- 206010008958 Chronic lymphocytic leukaemia Diseases 0.000 claims 2
- 206010017758 Gastric cancer Diseases 0.000 claims 2
- 206010020243 Hodgkin's disease Diseases 0.000 claims 2
- 201000006743 Hodgkin's lymphoma Diseases 0.000 claims 2
- 206010024324 Leukaemias Diseases 0.000 claims 2
- 208000000429 Leukemia, Lymphocytic, Chronic, B-Cell Diseases 0.000 claims 2
- 208000008456 Leukemia, Myelogenous, Chronic, BCR-ABL Positive Diseases 0.000 claims 2
- 208000007046 Leukemia, Myeloid, Acute Diseases 0.000 claims 2
- 206010025650 Malignant melanoma Diseases 0.000 claims 2
- 206010029592 Non-Hodgkin's lymphomas Diseases 0.000 claims 2
- 208000002154 Non-Small-Cell Lung Carcinoma Diseases 0.000 claims 2
- 108009000071 Non-small cell lung cancer Proteins 0.000 claims 2
- 206010033128 Ovarian cancer Diseases 0.000 claims 2
- 208000008443 Pancreatic Carcinoma Diseases 0.000 claims 2
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 2
- 206010060862 Prostate cancer Diseases 0.000 claims 2
- 206010038389 Renal cancer Diseases 0.000 claims 2
- 208000000587 Small Cell Lung Carcinoma Diseases 0.000 claims 2
- 206010041067 Small cell lung cancer Diseases 0.000 claims 2
- 210000001635 Urinary Tract Anatomy 0.000 claims 2
- 206010046766 Uterine cancer Diseases 0.000 claims 2
- 230000002730 additional Effects 0.000 claims 2
- 125000003806 alkyl carbonyl amino group Chemical group 0.000 claims 2
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims 2
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 claims 2
- 125000006598 aminocarbonylamino group Chemical group 0.000 claims 2
- 150000001450 anions Chemical class 0.000 claims 2
- 125000003710 aryl alkyl group Chemical group 0.000 claims 2
- 201000005216 brain cancer Diseases 0.000 claims 2
- CPELXLSAUQHCOX-UHFFFAOYSA-M bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims 2
- 229940006460 bromide ion Drugs 0.000 claims 2
- 201000010881 cervical cancer Diseases 0.000 claims 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 2
- 201000006934 chronic myeloid leukemia Diseases 0.000 claims 2
- 201000011231 colorectal cancer Diseases 0.000 claims 2
- 125000004122 cyclic group Chemical group 0.000 claims 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims 2
- 150000002430 hydrocarbons Chemical class 0.000 claims 2
- 201000002313 intestinal cancer Diseases 0.000 claims 2
- 238000001990 intravenous administration Methods 0.000 claims 2
- XMBWDFGMSWQBCA-UHFFFAOYSA-M iodide Chemical compound [I-] XMBWDFGMSWQBCA-UHFFFAOYSA-M 0.000 claims 2
- 229940006461 iodide ion Drugs 0.000 claims 2
- 201000010982 kidney cancer Diseases 0.000 claims 2
- 201000007270 liver cancer Diseases 0.000 claims 2
- 201000001441 melanoma Diseases 0.000 claims 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 2
- 201000009251 multiple myeloma Diseases 0.000 claims 2
- 229940006477 nitrate ion Drugs 0.000 claims 2
- GRYLNZFGIOXLOG-UHFFFAOYSA-N nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims 2
- 201000002528 pancreatic cancer Diseases 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 201000011549 stomach cancer Diseases 0.000 claims 2
- 125000001424 substituent group Chemical group 0.000 claims 2
- 125000003107 substituted aryl group Chemical group 0.000 claims 2
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 2
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- 201000005112 urinary bladder cancer Diseases 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 claims 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N D-Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 1
- 229960003552 Other antineoplastic agents in ATC Drugs 0.000 claims 1
- GGHNIFOFURESOA-UHFFFAOYSA-N [[4-[N'-[6-(4-chlorophenoxy)hexyl]-N-cyanocarbamimidoyl]iminopyridin-1-yl]-phenylmethyl] 2-[2-(2-methoxyethoxy)ethoxy]ethyl carbonate Chemical compound C1=CC(=NC(NC#N)=NCCCCCCOC=2C=CC(Cl)=CC=2)C=CN1C(OC(=O)OCCOCCOCCOC)C1=CC=CC=C1 GGHNIFOFURESOA-UHFFFAOYSA-N 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 125000000266 alpha-aminoacyl group Chemical group 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 125000006615 aromatic heterocyclic group Chemical group 0.000 claims 1
- 125000004429 atoms Chemical group 0.000 claims 1
- 239000007853 buffer solution Substances 0.000 claims 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 229910052801 chlorine Inorganic materials 0.000 claims 1
- 239000000460 chlorine Substances 0.000 claims 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 239000008103 glucose Substances 0.000 claims 1
- 125000004475 heteroaralkyl group Chemical group 0.000 claims 1
- 125000005549 heteroarylene group Chemical group 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 238000001802 infusion Methods 0.000 claims 1
- 238000010253 intravenous injection Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 125000004433 nitrogen atoms Chemical group N* 0.000 claims 1
- 239000000546 pharmaceutic aid Substances 0.000 claims 1
- 229940085991 phosphate ion Drugs 0.000 claims 1
- 125000005936 piperidyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims 1
- 239000011780 sodium chloride Substances 0.000 claims 1
- 239000000243 solution Substances 0.000 claims 1
- 150000003573 thiols Chemical class 0.000 claims 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 1
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US25207800P | 2000-11-21 | 2000-11-21 | |
PCT/DK2001/000750 WO2002042265A2 (en) | 2000-11-21 | 2001-11-14 | Cyanoguanidine prodrugs |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2004520282A JP2004520282A (ja) | 2004-07-08 |
JP2004520282A5 true JP2004520282A5 (ru) | 2005-12-22 |
JP4521157B2 JP4521157B2 (ja) | 2010-08-11 |
Family
ID=22954502
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2002544401A Expired - Lifetime JP4521157B2 (ja) | 2000-11-21 | 2001-11-14 | シアノグアニジンプロドラッグ |
Country Status (17)
Country | Link |
---|---|
US (1) | US6525077B2 (ru) |
EP (2) | EP1339686B1 (ru) |
JP (1) | JP4521157B2 (ru) |
KR (1) | KR100871577B1 (ru) |
CN (1) | CN100368401C (ru) |
AU (3) | AU1494702A (ru) |
BR (1) | BR0115514A (ru) |
CA (1) | CA2426601C (ru) |
CZ (1) | CZ305764B6 (ru) |
ES (2) | ES2643083T3 (ru) |
HK (2) | HK1073297A1 (ru) |
HU (1) | HU230544B1 (ru) |
IL (2) | IL155483A0 (ru) |
MX (1) | MXPA03004394A (ru) |
PL (1) | PL224371B1 (ru) |
RU (1) | RU2312858C2 (ru) |
WO (2) | WO2002042265A2 (ru) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9711123D0 (en) * | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
US20030045515A1 (en) * | 2001-05-24 | 2003-03-06 | Lise Binderup | Combination medicament for treatment of neoplastic diseases |
BR0309996A (pt) * | 2002-05-17 | 2005-02-22 | Leo Pharma As | Composto, composição farmacêutica, método de tratar ou melhorar doenças ou condições proliferativas, uso de um composto, e, método de tratar ou melhorar doenças inflamatórias |
US7253193B2 (en) | 2002-05-17 | 2007-08-07 | Leo Pharma A/S | Cyanoguanidine prodrugs |
RU2004136989A (ru) * | 2002-05-17 | 2005-06-27 | Лео Фарма А/С (Dk) | Цианогуанидиновые пролекарства |
US20050101576A1 (en) * | 2003-11-06 | 2005-05-12 | Novacea, Inc. | Methods of using vitamin D compounds in the treatment of myelodysplastic syndromes |
WO2004089925A1 (en) * | 2003-04-03 | 2004-10-21 | Semafore Pharmaceuticals, Inc. | Pi-3 kinase inhibitor prodrugs |
ES2572777T3 (es) | 2004-12-22 | 2016-06-02 | Leo Pharma A/S | Compuestos novedosos de cianoguanidina |
US9296697B2 (en) | 2005-08-24 | 2016-03-29 | Abbott Laboratories | Hetaryl-substituted guanidine compounds and use thereof as binding partners for 5-HT5-receptors |
CA2701071C (en) * | 2007-09-26 | 2018-03-27 | Gemin X Pharmaceuticals Canada Inc. | Compositions and methods for effecting nad+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
US8173677B2 (en) * | 2007-09-26 | 2012-05-08 | Gemin X Pharmaceuticals Canada Inc. | Compositions and methods for effecting NAD+ levels using a nicotinamide phosphoribosyl transferase inhibitor |
US8101606B2 (en) | 2007-11-12 | 2012-01-24 | Washington University | Neurofibromin pathway modulators |
AU2009286604B2 (en) | 2008-08-29 | 2015-05-28 | Onxeo Dk, Branch Of Onxeo S.A., France | Novel urea and thiourea derivatives |
CA2751495C (en) | 2009-02-06 | 2013-08-20 | Tianjin Hemay Bio-Tech Co., Ltd. | Pharmaceutical compositions comprising a pyridyl cyanoguanidine and cyclodextrin and/or derivatives thereof |
CA2768338A1 (en) | 2009-07-17 | 2011-01-20 | Topotarget A/S | Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors |
US9224007B2 (en) * | 2009-09-15 | 2015-12-29 | International Business Machines Corporation | Search engine with privacy protection |
US9600134B2 (en) | 2009-12-29 | 2017-03-21 | International Business Machines Corporation | Selecting portions of computer-accessible documents for post-selection processing |
US8912184B1 (en) | 2010-03-01 | 2014-12-16 | Alzheimer's Institute Of America, Inc. | Therapeutic and diagnostic methods |
WO2011121055A1 (en) | 2010-03-31 | 2011-10-06 | Topotarget A/S | Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety |
EP2611778B1 (en) | 2010-09-03 | 2015-08-05 | Forma TM, LLC. | Guanidine compounds and compositions for the inhibition of nampt |
JP2014514300A (ja) * | 2011-04-08 | 2014-06-19 | スファエラ ファーマ ピーティーイー リミテッド | 置換メチルホルミル試薬並びに化合物の物理化学的性質及び/又は薬物動態学的性質を改質するためのそれらの使用方法 |
US9195853B2 (en) | 2012-01-15 | 2015-11-24 | International Business Machines Corporation | Automated document redaction |
EP2861588A4 (en) * | 2012-06-15 | 2016-04-20 | Univ California | NEW THERAPEUTIC AGENTS FOR BRAIN CANCER |
WO2014004884A1 (en) * | 2012-06-27 | 2014-01-03 | Alzheimer's Institute Of America, Inc. | Compounds and therapeutic uses thereof |
WO2014055938A1 (en) * | 2012-10-04 | 2014-04-10 | Inhibikase Therapeutics, Inc. | Novel compounds, their preparation and their uses |
US9892278B2 (en) | 2012-11-14 | 2018-02-13 | International Business Machines Corporation | Focused personal identifying information redaction |
US10227333B2 (en) | 2015-02-11 | 2019-03-12 | Curtana Pharmaceuticals, Inc. | Inhibition of OLIG2 activity |
WO2016138479A1 (en) | 2015-02-27 | 2016-09-01 | Curtana Pharmaceuticals, Inc. | Inhibition of olig2 activity |
WO2017162536A1 (en) | 2016-03-21 | 2017-09-28 | H. Lundbeck A/S | Vortioxetine prodrugs |
WO2018199174A1 (ja) * | 2017-04-25 | 2018-11-01 | 生化学工業株式会社 | 第3級アミン化合物又はイミン化合物-ポリマーコンジュゲートとその製造方法 |
EP3590927A1 (en) * | 2018-07-05 | 2020-01-08 | Bayer Animal Health GmbH | Novel compounds for controlling arthropods |
US11174229B2 (en) * | 2018-10-29 | 2021-11-16 | Kempharm, Inc. | D-amphetamine compounds, compositions, and processes for making and using the same |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH05501103A (ja) * | 1989-06-26 | 1993-03-04 | ザ・リサーチ・ファウンデーション・オヴ・ステイト・ユニヴァーシティ・オヴ・ニューヨーク | ビス―アシルオキシメチル誘導体 |
GB9219472D0 (en) | 1992-09-15 | 1992-10-28 | Leo Pharm Prod Ltd | Chemical compounds |
GB9607219D0 (en) * | 1996-04-04 | 1996-06-12 | Smithkline Beecham Plc | Novel compounds |
GB9711119D0 (en) | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
GB9711125D0 (en) | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
GB9711123D0 (en) | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
GB9711124D0 (en) | 1997-05-29 | 1997-07-23 | Leo Pharm Prod Ltd | Novel cyanoguanidines |
WO2000061559A1 (en) * | 1999-04-09 | 2000-10-19 | Shionogi Bioresearch Corp. | N-substituted cyanoguanidine compounds |
AU4080300A (en) * | 1999-04-09 | 2000-11-14 | Shionogi Bioresearch Corp. | Cyanoguanidine compounds |
-
2001
- 2001-11-12 AU AU1494702A patent/AU1494702A/xx active Pending
- 2001-11-14 CA CA2426601A patent/CA2426601C/en not_active Expired - Lifetime
- 2001-11-14 MX MXPA03004394A patent/MXPA03004394A/es active IP Right Grant
- 2001-11-14 RU RU2003118446/04A patent/RU2312858C2/ru active
- 2001-11-14 HU HU0400564A patent/HU230544B1/hu unknown
- 2001-11-14 EP EP01983436.5A patent/EP1339686B1/en not_active Expired - Lifetime
- 2001-11-14 ES ES15150976.7T patent/ES2643083T3/es not_active Expired - Lifetime
- 2001-11-14 CN CNB018192440A patent/CN100368401C/zh not_active Expired - Lifetime
- 2001-11-14 EP EP15150976.7A patent/EP2894149B1/en not_active Expired - Lifetime
- 2001-11-14 CZ CZ2003-1303A patent/CZ305764B6/cs not_active IP Right Cessation
- 2001-11-14 WO PCT/DK2001/000750 patent/WO2002042265A2/en active IP Right Grant
- 2001-11-14 AU AU2002214947A patent/AU2002214947B2/en not_active Expired
- 2001-11-14 BR BR0115514-8A patent/BR0115514A/pt active Pending
- 2001-11-14 IL IL15548301A patent/IL155483A0/xx unknown
- 2001-11-14 KR KR1020037006880A patent/KR100871577B1/ko active IP Right Grant
- 2001-11-14 JP JP2002544401A patent/JP4521157B2/ja not_active Expired - Lifetime
- 2001-11-14 ES ES01983436.5T patent/ES2549260T3/es not_active Expired - Lifetime
- 2001-11-14 PL PL362864A patent/PL224371B1/pl unknown
- 2001-11-20 AU AU2002223511A patent/AU2002223511A1/en not_active Abandoned
- 2001-11-20 US US09/988,819 patent/US6525077B2/en not_active Expired - Lifetime
- 2001-11-20 WO PCT/DK2001/000770 patent/WO2002042276A1/en not_active Application Discontinuation
-
2003
- 2003-04-15 IL IL155483A patent/IL155483A/en active IP Right Grant
-
2005
- 2005-07-11 HK HK05105842A patent/HK1073297A1/xx not_active IP Right Cessation
-
2016
- 2016-01-15 HK HK16100480.9A patent/HK1212678A1/zh not_active IP Right Cessation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2004520282A5 (ru) | ||
RU2003118446A (ru) | Пролекарства цианогуанидина | |
JP4521157B2 (ja) | シアノグアニジンプロドラッグ | |
RU2012151012A (ru) | Циклопропиловые дикарбоксамиды и аналоги, обладающие противораковым и антипролиферативным действием | |
RU2006132288A (ru) | Производные пиразолопиримидина, как ингибиторы циклин-зависимой киназы | |
RU2013135662A (ru) | Замещенные соединения хинолина и способы их использования | |
EP3612526A2 (en) | K-ras modulators | |
JP2013525458A5 (ru) | ||
JP2013544846A5 (ru) | ||
JP2018515492A5 (ru) | ||
RU2015118145A (ru) | Замещенные бензольные соединения | |
JP2008528467A5 (ru) | ||
RU2005103610A (ru) | Комбинации лекарственных средств для лечения новообразований | |
CN111617078B (zh) | 用于疾病治疗和/或预防的药物组合物、方法及其用途 | |
RU2013109143A (ru) | Бензимидазол- и азабензимидазолсодержащие соединения, которые ингибируют киназу анапластической лимфомы | |
RU2015118647A (ru) | Аминопиримидиновые соединения в качестве ингибиторов содержащих т790м мутантных egfr | |
RU2014125230A (ru) | Пиридонамиды и их аналоги, демонстрирующие противораковую и антипролиферативную активность | |
WO2003047579B1 (en) | Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers | |
CO5640124A2 (es) | Combinacion de un antagonista de mglur2 y un inhibidor de ache para el tratamiento de trastornos neurologicos agudos y/o cronicos | |
RU2015106605A (ru) | Соединения замещенных пиразолонов и способы использования | |
JP2016503414A5 (ru) | ||
RU2003137007A (ru) | Новые пиридилцианогуанидиновые соединения | |
RU2009146376A (ru) | Способы применения антагонистов вазопрессина с антрациклиновыми химиотерапевтическими средствами для снижения кардиотоксичности и/или улучшения выживания | |
RU2004136989A (ru) | Цианогуанидиновые пролекарства | |
RU2004136991A (ru) | Цианогуанидиновые пролекарства |